ly 274614 has been researched along with Seizures in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Borowicz, KK; Czuczwar, SJ; Gasior, M; Kleinrok, Z | 1 |
| Borowicz, K; Czuczwar, SJ; Gasior, M; Kleinrok, Z; Starownik, R | 1 |
2 other study(ies) available for ly 274614 and Seizures
| Article | Year |
|---|---|
Competitive NMDA-receptor antagonists, LY 235959 and LY 233053, enhance the protective efficacy of various antiepileptic drugs against maximal electroshock-induced seizures in mice.
Topics: Animals; Anticonvulsants; Avoidance Learning; Disease Models, Animal; Drug Synergism; Electroshock; Epilepsy; Excitatory Amino Acid Antagonists; Female; Humans; Isoquinolines; Kindling, Neurologic; Memory; Mice; Motor Activity; Pipecolic Acids; Receptors, N-Methyl-D-Aspartate; Seizures; Tetrazoles | 1996 |
Anticonvulsant and adverse effects of MK-801, LY 235959, and GYKI 52466 in combination with Ca2+ channel inhibitors in mice.
Topics: Animals; Anti-Anxiety Agents; Anticonvulsants; Avoidance Learning; Benzodiazepines; Calcium Channel Blockers; Dizocilpine Maleate; Drug Interactions; Electroshock; Excitatory Amino Acid Antagonists; Flunarizine; Isoquinolines; Male; Mice; Motor Activity; Nicardipine; Nifedipine; Seizures | 1997 |